Lifeward Ltd. (LFWD) is a publicly traded company in the Healthcare — Medical - Devices industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Lifeward Ltd. is a healthcare technology company specializing in the creation, development, and commercialization of wearable robotic exoskeletons. These sophisticated devices are engineered to restore lower limb mobility for individuals living with spinal cord injuries (SCI), granting them the ability to stand, walk, pivot, and navigate staircases by providing assistive hip and knee motion.
Analysis Summary
Lifeward Ltd. reported revenue of $22.0M in the most recent fiscal year, growing at a 5-year CAGR of 38.1%.
Trailing-twelve-month margins: gross margin 36.0%, operating margin -104.2%, net margin -141.3%.
At the current price of $6.91, LFWD has negative trailing earnings (P/E not meaningful) and an ROE of -236.85%. Market capitalisation stands at $11M.
Balance sheet quality for LFWD: current ratio of 1.3, net debt of $2.2M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $6.91 |
| Market Cap | $11M |
| Exchange | NASDAQ |
| Country | IL |
Valuation Ratios
| Price / Book | 1.58 |
| EV / EBITDA | -4.27 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -236.85% |
| Return on Invested Capital | -119.56% |
| Return on Assets | -86.96% |
| Gross Margin | 35.95% |
| Operating Margin | -104.25% |
| Net Margin | -141.28% |
Financial Health
| Debt / Equity | 0.21 |
| Current Ratio | 1.24 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -15.36 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| LFWD | Lifeward Ltd. | $11M | 1.58 | -236.8% | |
| ABT | Abbott Laboratories | $177.1B | 32.49 | 3.45 | 10.5% |
| 0Y6X.L | Medtronic Plc | $125.7B | |||
| MDT | Medtronic plc | $118.5B | 22.97 | 2.39 | 10.6% |
| SYK | Stryker Corporation | $109.2B | 29.95 | 4.66 | 16.4% |
| 0R2S.L | Stryker Corporation | $107.9B | 28.37 | 4.41 | 16.4% |
| 0HOY.L | Boston Scientific Corporation | $65.3B | 17.84 | 2.62 | 14.9% |
| BSX | Boston Scientific Corporation | $65.3B | 17.73 | 2.61 | 14.9% |
Price Performance
| 1 month | -6.75% |
| 3 months | +0.00% |
| Year-to-date | -0.14% |
| 1 year | +5.02% |
| 3 years | -89.95% |
| 5 years | -93.91% |
52-Week Range
| 52-week High | $10.56 |
| 52-week Low | $4.14 |
| Avg Volume (90d) | 10K |
Related companies: DHAI · IINN · INAB · LYRA · PTHL · RNAZ · SBFM
Explore sector: Healthcare · Medical - Devices
More sections of LFWD: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks